IMNN Imunon, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 749647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-4.9%
TTM EPS YoY60.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-448.6%
ROA-143.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets78.2%
Debt / equity0.00x
Current ratio1.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $7.78M | $11.64M |
| SG&A expense | $6.87M | $7.49M |
| Operating income | -$14.65M | -$19.13M |
| Pretax income | $14.50M | $18.60M |
| Net income | -$14.50M | -$18.62M |
| EBITDA | -$14.36M | -$18.89M |
| EPS (basic) | -6.83 | -16.94 |
| EPS (diluted) | -6.83 | -16.94 |
| Weighted avg. shares (diluted) | 2.12M | 1.10M |
| Balance sheet | ||
| Cash & equivalents | $8.78M | $5.87M |
| Current assets | $10.72M | $8.01M |
| PP&E, net | $529,936 | $541,272 |
| Total assets | $12.29M | $9.72M |
| Current liabilities | $4.62M | $4.79M |
| Total liabilities | $5.23M | $5.47M |
| Shareholders' equity | $7.06M | $4.24M |
| Shares outstanding | 3.42M | 966,712 |
| Cash flow statement | ||
| Operating cash flow | -$13.90M | -$18.85M |
| Capital expenditure | $280,572 | $29,541 |
| Free cash flow | -$14.18M | -$18.88M |
| Investing cash flow | -$280,572 | $9.83M |
| Financing cash flow | $17.09M | $9.06M |
| Depreciation & amortization | $291,908 | $240,175 |
| Stock-based compensation | $127,374 | $477,256 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.